Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis
Abstract
:1. Introduction
2. Mechanisms of BoNT-A
3. Clinical Evidence of Intravesical BoNT-A for BPS/IC
4. Conclusions
Author Contributions
Conflicts of Interest
References
- Van de Merwe, J.P.; Nordling, J.; Bouchelouche, P.; Bouchelouche, K.; Cervigni, M.; Daha, L.K.; Elneil, S.; Fall, M.; Hohlbrugger, G.; Irwin, P.; et al. Diagnostic criteria, classification, and nomenclature for painfulbladder syndrome/interstitial cystitis: An ESSIC proposal. Eur. Urol. 2008, 53, 60–67. [Google Scholar] [CrossRef] [PubMed]
- Hanno, P.M.; Burks, D.A.; Clemens, J.Q.; Dmochowski, R.R.; Erickson, D.; Fitzgerald, M.P.; Forrest, J.B.; Gordon, B.; Gray, M.; Mayer, R.D.; et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J. Urol. 2011, 185, 2162–2170. [Google Scholar] [CrossRef] [PubMed]
- Curhan, G.C.; Speizer, F.E.; Hunter, D.J.; Curhan, S.G.; Stampfer, M.J. Epidemiology of interstitial cystitis: A population based study. J. Urol. 1999, 161, 549–552. [Google Scholar] [CrossRef]
- Mayer, R. Interstitial cystitis pathogenesis and treatment. Curr. Opin. Infect. Dis. 2007, 20, 77–82. [Google Scholar] [CrossRef] [PubMed]
- Nazif, O.; Teichman, J.M.; Gebhart, G.F. Neural upregulation in interstitial cystitis. Urology 2007, 69, 24–33. [Google Scholar] [CrossRef] [PubMed]
- Sant, G.R.; Kempuraj, D.; Marchand, J.E.; Theoharides, T.C. The mast cell in interstitial cystitis: Role in pathophysiology and pathogenesis. Urology 2007, 69, 34–40. [Google Scholar] [CrossRef] [PubMed]
- Van de Merwe, J.P.; Yamada, T.; Sakamoto, Y. Systemic aspects of interstitial cystitis, immunology and linkage with autoimmune disorders. Int. J. Urol. 2003, 10 (Suppl. 1), S35–S38. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.T.; Kuo, H.C. Biomarkers for patients with interstitial cystitis/bladder pain syndrome. Urol. Sci. 2015, 26, 225–229. [Google Scholar] [CrossRef]
- Lee, C.L.; Peng, C.H.; Kuo, H.C. Therapeutic effects and predictive factors for successful intravesical hyaluronic acid instillation in patients with interstitial cystitis/bladder pain syndrome. Urol. Sci. 2015, 26, 125–130. [Google Scholar] [CrossRef]
- Scott, A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J. Pediatr. Ophthalmol. Strabismus 1980, 17, 21–25. [Google Scholar] [CrossRef]
- Oh, H.M.; Chung, M.E. Botulinum Toxin for Neuropathic Pain: A Review of the Literature. Toxins (Basel.) 2015, 7, 3127–3154. [Google Scholar] [CrossRef] [PubMed]
- Chuang, Y.C.; Yoshimura, N.; Huang, C.C.; Chiang, P.H.; Chancellor, M.B. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain response in rats. J. Urol. 2004, 172, 1529–1532. [Google Scholar] [CrossRef] [PubMed]
- Kuo, H.C.; Liu, H.T.; Chuang, Y.C.; Birder, L.A.; Chancellor, M.B. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: A single-center study. Eur. Urol. 2014, 65, 1117–1124. [Google Scholar] [CrossRef] [PubMed]
- Hung, S.Y.; Chancellor, D.D.; Chancellor, M.B.; Chuang, Y.C. Role of liposome in treatment of overactive bladder and interstitial cystitis. Urol. Sci. 2015, 26, 3–6. [Google Scholar] [CrossRef]
- Dykstra, D.D.; Sidi, A.A.; Scott, A.B.; Pagel, J.M.; Goldish, G.D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. 1988, 39, 919–922. [Google Scholar]
- Smith, C.P.; Radziszewski, P.; Borkowski, A.; Somogyi, G.T.; Boone, T.B.; Chancellor, M.B. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 2004, 64, 871–875. [Google Scholar] [CrossRef] [PubMed]
- Lam, K.H.; Yao, G.; Jin, R. Diverse binding modes, same goal: The receptor recognition mechanism of botulinum neurotoxin. Prog. Biophys. Mol. Biol. 2015, 117, 225–231. [Google Scholar] [CrossRef] [PubMed]
- Lucioni, A.; Bales, G.T.; Lotan, T.L.; McGehee, D.S.; Cook, S.P.; Rapp, D.E. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008, 101, 366–370. [Google Scholar] [CrossRef] [PubMed]
- Peng, C.H.; Jhang, J.F.; Shie, J.H.; Kuo, H.C. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis—Clinical results and immunohistochemistry analysis. Urology 2013, 82. [Google Scholar] [CrossRef]
- Apostolidis, A.; Dasgupta, P.; Fowler, C.J. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur. Urol. 2006, 49, 644–650. [Google Scholar] [CrossRef] [PubMed]
- Cui, M.; Khanijou, S.; Rubino, J.; Aoki, K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107, 125–133. [Google Scholar] [CrossRef] [PubMed]
- Welch, M.J.; Purkiss, J.R.; Foster, K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000, 38, 245–258. [Google Scholar] [CrossRef]
- Durham, P.L.; Cady, R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache 2004, 44, 35–42. [Google Scholar] [CrossRef] [PubMed]
- Chuang, Y.C.; Yoshimura, N.; Huang, C.C.; Wu, M.; Chiang, P.H.; Chancellor, M.B. Intraprostatic botulinum toxin A injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. J. Urol. 2008, 180, 742–748. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.T.; Kuo, H.C. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007, 70, 463–468. [Google Scholar] [CrossRef] [PubMed]
- Xiao, L.; Cheng, J.; Zhuang, Y.; Qu, W.; Muir, J.; Liang, H.; Zhang, D. Botulinum toxin type A reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain. Pain Med. 2013, 14, 276–286. [Google Scholar] [CrossRef] [PubMed]
- Liu, B.L.; Yang, F.; Zhan, H.L.; Feng, Z.Y.; Zhang, Z.G.; Li, W.B.; Zhou, X.F. Increased severity of inflammation correlates with elevated expression of TRPV1 nerve fibers and nerve growth factor on interstitial cystitis/bladder pain syndrome. Urol. Int. 2014, 92, 202–208. [Google Scholar] [CrossRef] [PubMed]
- Apostolidis, A.; Popat, R.; Yiangou, Y.; Cockayne, D.; Ford, A.P.; Davis, J.B.; Dasgupta, P.; Fowler, C.J.; Anand, P. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J. Urol. 2005, 174, 977–982. [Google Scholar] [CrossRef] [PubMed]
- Avelino, A.; Cruz, C.; Nagy, I.; Cruz, F. Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience 2002, 109, 787–798. [Google Scholar] [CrossRef]
- Pinto, R.; Lopes, T.; Frias, B.; Silva, A.; Silva, J.A.; Silva, C.M.; Cruz, C.; Cruz, F.; Dinis, P. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur. Urol. 2010, 58, 360–365. [Google Scholar] [CrossRef] [PubMed]
- Giannantoni, A.; Costantini, E.; Di Stasi, S.M.; Tascini, M.C.; Bini, V.; Porena, M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: A pilot study. Eur. Urol. 2006, 49, 704–709. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chung, S.D.; Kuo, Y.C.; Kuo, H.C. Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Phys. 2012, 15, 197–202. [Google Scholar]
- Giannantoni, A.; Porena, M.; Costantini, E.; Zucchi, A.; Mearini, L.; Mearini, E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-Year followup. J. Urol. 2008, 179, 1031–1034. [Google Scholar] [CrossRef] [PubMed]
- Kuo, H.C.; Chancellor, M.B. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009, 104, 657–661. [Google Scholar] [CrossRef] [PubMed]
- Akiyama, Y.; Nomiya, A.; Niimi, A.; Yamada, Y.; Fujimura, T.; Nakagawa, T.; Fukuhara, H.; Kume, H.; Igawa, Y.; Homma, Y. Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response. Int. J. Urol. 2015, 22, 835–841. [Google Scholar] [CrossRef] [PubMed]
- Kuo, H.C.; Jiang, Y.H.; Tsai, Y.C.; Kuo, Y.C. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment—A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol. Urodyn. 2016, 35, 609–614. [Google Scholar] [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chiu, B.; Tai, H.-C.; Chung, S.-D.; Birder, L.A. Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis. Toxins 2016, 8, 201. https://doi.org/10.3390/toxins8070201
Chiu B, Tai H-C, Chung S-D, Birder LA. Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis. Toxins. 2016; 8(7):201. https://doi.org/10.3390/toxins8070201
Chicago/Turabian StyleChiu, Bin, Huai-Ching Tai, Shiu-Dong Chung, and Lori A. Birder. 2016. "Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis" Toxins 8, no. 7: 201. https://doi.org/10.3390/toxins8070201
APA StyleChiu, B., Tai, H. -C., Chung, S. -D., & Birder, L. A. (2016). Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis. Toxins, 8(7), 201. https://doi.org/10.3390/toxins8070201